Casein glycomacropeptide (CGMP) is a bioactive peptide derived from cheese whey during the enzymatic digestion of casein. Scientific studies have investigated its effects on the small intestine, primarily due to its prebiotic properties and its ability to modulate gut microbiota. CGMP is rich in sialic acid and lacks aromatic amino acids, which makes it especially useful in managing metabolic conditions like phenylketonuria (PKU). Regarding intestinal support, research shows that CGMP can promote the growth of beneficial bacteria such as Bifidobacterium and Lactobacillus species, which are important for maintaining a healthy intestinal environment and supporting gut barrier function.

Several animal and in vitro studies (e.g., Brody et al., 2000; Nakano et al., 2001) have demonstrated that CGMP supplementation can enhance short-chain fatty acid production by gut microbes, reduce intestinal inflammation, and improve mucosal integrity. Additionally, CGMP may inhibit the binding of pathogenic bacteria to intestinal epithelial cells, thus supporting immune defense in the gut. However, more high-quality human clinical trials are needed to fully confirm and quantify these effects in the context of small intestine health.

In summary, there is a moderate level of scientific evidence supporting the use of casein glycomacropeptide to support small intestine health, primarily through its prebiotic effects and its influence on gut microbiota composition and intestinal barrier function.